Daniel Kuritzkes

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo
    Athe M N Tsibris
    Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e5683. 2009
  2. pmc Drug resistance in HIV-1
    Daniel R Kuritzkes
    Division of Infectious Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Curr Opin Virol 1:582-9. 2011
  3. pmc Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists
    Timothy J Henrich
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 56:1931-5. 2012
  4. ncbi request reprint Extending antiretroviral therapy to resource-poor settings: implications for drug resistance
    Daniel R Kuritzkes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Division of AIDS, Harvard Medical School, Boston, MA, USA
    AIDS 18:S45-8. 2004
  5. ncbi request reprint Preventing and managing antiretroviral drug resistance
    Daniel R Kuritzkes
    Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts, USA
    AIDS Patient Care STDS 18:259-73. 2004
  6. doi request reprint Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects
    Daniel R Kuritzkes
    Brigham and Women s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
    J Infect Dis 197:867-70. 2008
  7. ncbi request reprint Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s
    Daniel R Kuritzkes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Cambridge, MA 02139, USA
    J Infect Dis 195:1169-76. 2007
  8. ncbi request reprint Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1
    Daniel R Kuritzkes
    Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA
    J Infect Dis 189:286-91. 2004
  9. ncbi request reprint Preventing and managing resistance in the clinical setting
    Daniel R Kuritzkes
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Acquir Immune Defic Syndr 34:S103-10. 2003
  10. ncbi request reprint Quantification of human immunodeficiency virus type 1 by reverse transcriptase-coupled polymerase chain reaction
    Daniel R Kuritzkes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, 65 Landsdowne Street, Cambridge, MA 02139, USA
    J Infect Dis 190:2047-54. 2004

Research Grants

  1. HIV-1 resistance to nucleoside analogues
    Daniel Kuritzkes; Fiscal Year: 2004
  2. HIV-1 Resistance to Chemokine Receptor Antagonists
    Daniel Kuritzkes; Fiscal Year: 2007
  3. HIV-1 THERAPEUTICS AND DRUG RESISTANCE
    Daniel Kuritzkes; Fiscal Year: 2005
  4. HIV-1 DUAL RESISTANCE TO AZT AND 3TC
    Daniel Kuritzkes; Fiscal Year: 2000
  5. HIV-1 THERAPEUTICS AND DRUG RESISTANCE
    Daniel Kuritzkes; Fiscal Year: 2009
  6. Fitness of Enfuvirtide-(T-20)-Resistant HIV-1
    Daniel Kuritzkes; Fiscal Year: 2006
  7. Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTU
    Daniel Kuritzkes; Fiscal Year: 2007
  8. HIV-1 THERAPEUTICS AND DRUG RESISTANCE
    Daniel Kuritzkes; Fiscal Year: 2007
  9. Fitness of Enfuvirtide-(T-20)-Resistant HIV-1
    Daniel Kuritzkes; Fiscal Year: 2003
  10. HIV-1 THERAPEUTICS AND DRUG RESISTANCE
    Daniel R Kuritzkes; Fiscal Year: 2010

Detail Information

Publications106 found, 100 shown here

  1. pmc Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo
    Athe M N Tsibris
    Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e5683. 2009
    ..Greater V3 diversity was observed post-selection. This previously unreported degree of V3 loop sequence diversity has implications for viral pathogenesis, vaccine design, and the optimal use of HIV-1 CCR5 antagonists...
  2. pmc Drug resistance in HIV-1
    Daniel R Kuritzkes
    Division of Infectious Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Curr Opin Virol 1:582-9. 2011
    ..This review summarizes recent information on antiretroviral drug resistance...
  3. pmc Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists
    Timothy J Henrich
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 56:1931-5. 2012
    ..This heterogeneity makes it difficult to draw general conclusions about the relationship between patterns of CCR5 antagonist resistance and the use of specific CCR5 domains for entry...
  4. ncbi request reprint Extending antiretroviral therapy to resource-poor settings: implications for drug resistance
    Daniel R Kuritzkes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Division of AIDS, Harvard Medical School, Boston, MA, USA
    AIDS 18:S45-8. 2004
    ....
  5. ncbi request reprint Preventing and managing antiretroviral drug resistance
    Daniel R Kuritzkes
    Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts, USA
    AIDS Patient Care STDS 18:259-73. 2004
    ..Because "archived" resistant HIV may emerge quickly once treatment is initiated, we need to keep this in mind when selecting initial therapy...
  6. doi request reprint Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects
    Daniel R Kuritzkes
    Brigham and Women s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
    J Infect Dis 197:867-70. 2008
    ..27 [95% confidence interval], 1.15-4.49; P = .018). These results support resistance testing before starting antiretroviral therapy...
  7. ncbi request reprint Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s
    Daniel R Kuritzkes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Cambridge, MA 02139, USA
    J Infect Dis 195:1169-76. 2007
    ..We sought to compare clearance rates of plasma human immunodeficiency virus type 1 (HIV-1) RNA in men and women starting triple-nucleoside-based versus efavirenz (EFV)-based regimens...
  8. ncbi request reprint Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1
    Daniel R Kuritzkes
    Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA
    J Infect Dis 189:286-91. 2004
    ..We wished to determine the safety and anti-human immunodeficiency virus (HIV) type 1 activity of single doses of TNX-355, a humanized IgG4 anti-CD4 monoclonal antibody with potent activity against HIV-1 in vitro, in HIV-infected subjects...
  9. ncbi request reprint Preventing and managing resistance in the clinical setting
    Daniel R Kuritzkes
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Acquir Immune Defic Syndr 34:S103-10. 2003
  10. ncbi request reprint Quantification of human immunodeficiency virus type 1 by reverse transcriptase-coupled polymerase chain reaction
    Daniel R Kuritzkes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, 65 Landsdowne Street, Cambridge, MA 02139, USA
    J Infect Dis 190:2047-54. 2004
  11. ncbi request reprint Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens
    Daniel R Kuritzkes
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 36:600-3. 2004
    ..This randomized study shows that TAMs accumulate at similar rates during treatment with ZDV or d4T, but the specific pattern of mutations may differ somewhat in patients treated with these thymidine analogues...
  12. ncbi request reprint Ethical conduct of research in resource-limited settings
    Daniel R Kuritzkes
    Brigham and Women s Hospital, Cambridge, Massachusetts 02139, USA
    J Infect Dis 189:764-5. 2004
  13. ncbi request reprint Resistance to protease inhibitors
    Daniel R Kuritzkes
    Partners AIDS Research Center, Cambridge, MA 02139, USA
    J HIV Ther 7:87-91. 2002
    ..Resistance may be overcome by pharmacological enhancement of plasma PI levels, but newer drugs that are active against PI-resistant viruses are needed...
  14. pmc HIV-1 entry inhibitors: an overview
    Daniel R Kuritzkes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02139, USA
    Curr Opin HIV AIDS 4:82-7. 2009
    ..To provide an overview of HIV-1 entry inhibitors, with a focus on chemokine receptor antagonists...
  15. pmc Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System
    Daniel R Kuritzkes
    Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Clin Microbiol 41:1594-9. 2003
    ..The TRUGENE HIV-1 Genotyping Kit and OpenGene DNA Sequencing System consistently generate highly accurate sequence data when tested with IMC-derived HIV and patient samples...
  16. pmc Lensless imaging for point-of-care testing
    Sangjun Moon
    Bio Acoustic MEMS in Medicine Laboratory, Center for Bioengineering, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Conf Proc IEEE Eng Med Biol Soc 2009:6376-9. 2009
    ..5 +/- 2.4% overall platform performance (n = 9 devices). This integrated platform has potential for point-of-care testing (POCT) to rapidly capture, image and count specific cell types from unprocessed whole blood...
  17. ncbi request reprint MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study
    David W Haas
    Division of Infectious Diseases, Vanderbilt University School of Medicine, 345 24th Avenue, North, Suite 105, Nashville, TN 37212, USA
    J Acquir Immune Defic Syndr 34:295-8. 2003
    ..It is concluded with 95% confidence that phase 1 viral decay differences between exon 26 TT and CC groups are unlikely to exceed 18%...
  18. ncbi request reprint Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Infect Dis 190:257-66. 2004
    ..These findings provide evidence that increased HIV-1 replication during filgrastim treatment was associated with activation of HIV-1 variants that, before filgrastim treatment, were minor components of the plasma quasi species...
  19. pmc HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
    Robert W Shafer
    Division of Infectious Diseases, Stanford University, Stanford, California, USA
    AIDS 21:215-23. 2007
    ..However, such programs will not produce comparable estimates unless a standardized list of drug-resistance mutations is used to define transmitted resistance...
  20. pmc Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine
    Thomas C Stoeckli
    Division of Infectious Diseases, Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver 80262, USA
    Antimicrob Agents Chemother 46:4000-3. 2002
    ..Sequences from the Stanford HIV RT and Protease Sequence Database showed that these mutations were more common in HIV-1 isolates from patients treated with zidovudine and lamivudine than in patients not treated with these drugs...
  21. pmc Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy
    Roger Paredes
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    AIDS 24:45-53. 2010
    ..Pregnancy-limited antiretroviral therapy (PLAT) drastically reduces HIV-1 transmission to the newborn, but may select for antiretroviral drug resistance mutations in mothers...
  22. pmc Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure
    Roger Paredes
    Brigham and Women s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
    J Infect Dis 201:662-71. 2010
    ..The clinical relevance of detecting minority drug-resistant human immunodeficiency virus type 1 (HIV-1) variants is uncertain...
  23. ncbi request reprint HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course
    Allan R Tenorio
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Acquir Immune Defic Syndr 34:491-6. 2003
    ..HIV-specific CD4+ T-cell immunity was detected in most subjects with low-level and undetectable viremia and may have a role in controlling viremia in the setting of partial suppression...
  24. doi request reprint Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 197:1006-10. 2008
    ..There were no significant differences among subgroups with respect to treatment responses. These results demonstrate the potency of efavirenz-containing regimens across a spectrum of pretreatment VLs and CD4 counts...
  25. ncbi request reprint Assessing resistance costs of antiretroviral therapies via measures of future drug options
    Hongyu Jiang
    Department of Biostatistics, Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 188:1001-8. 2003
    ..Quantification of future drug options as an outcome of antiretroviral therapy trials may complement traditional clinical, virologic, and immunologic end points, thereby providing novel insights...
  26. pmc Antiretroviral therapies in women after single-dose nevirapine exposure
    Shahin Lockman
    Brigham and Women s Hospital, Boston, MA, USA
    N Engl J Med 363:1499-509. 2010
    ..Peripartum administration of single-dose nevirapine reduces mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) but selects for nevirapine-resistant virus...
  27. pmc Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection
    Eric S Rosenberg
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 5:e10555. 2010
    ..clinicaltrials.gov NCT00125099)..
  28. ncbi request reprint Design issues in initial HIV-treatment trials: focus on ACTG A5095
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, USA
    Antivir Ther 11:751-60. 2006
    ..We also hope to inform the field regarding issues in choosing composite versus virological endpoints as well as other key considerations in trial design and monitoring...
  29. ncbi request reprint Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Infect Dis 41:236-42. 2005
    ..Available data suggest that lamivudine contributes to partial viral suppression, despite the presence of M184V mutations and high-level phenotypic lamivudine resistance...
  30. ncbi request reprint Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness
    Jing Lu
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Acquir Immune Defic Syndr 40:20-3. 2005
    ..Analyzing viral fitness can provide important insights into the role of polymorphisms in drug resistance...
  31. pmc The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations
    Luis R Miranda
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, and Division of AIDS, Harvard Medical School, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 49:2648-56. 2005
    ....
  32. pmc Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa
    Vincent C Marconi
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02139, USA
    Clin Infect Dis 46:1589-97. 2008
    ..The prevalence of resistance was assessed among patients from KwaZulu Natal, South Africa, following failure of their first highly active antiretroviral therapy (HAART) regimen...
  33. pmc Development of dual-class antiretroviral drug resistance in a child coinfected with HIV and tuberculosis: a case report from KwaZulu-Natal, South Africa
    Richard A Murphy
    Massachusetts General Hospital, and Brigham and Women s Hospital, Boston, MA, USA
    J Trop Pediatr 55:60-2. 2009
    ..We report on a child initiated on this regimen, during concurrent TB treatment, who promptly developed an adverse reaction, virologic failure and dual-class antiretroviral drug resistance, compromising subsequent salvage ART...
  34. pmc Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1
    Zixin Hu
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, 65 Landsdowne Street, Cambridge, MA 02139, USA
    J Virol 80:7020-7. 2006
    ..These results help explain why T215Y but not T215F usually emerges as the first major TAM, as well as the clustering of L210W with TAM-1 mutations and T215F with TAM-2 mutations...
  35. pmc Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency
    Elias K Halvas
    Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, S818 Scaife Hall, 3550 Terrace St, Pittsburgh, PA 15261, and Children s Hospital of Los Angeles, CA, USA
    J Clin Microbiol 44:2612-4. 2006
    ..1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy...
  36. pmc Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations
    Michelle Marcial
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, 65 Landsdowne Street, Room 449, Cambridge, MA 02139, USA
    J Clin Microbiol 44:3384-7. 2006
    ..Resulting sequence data were highly accurate compared to a "home brew" assay and clonal sequence analysis...
  37. pmc Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy
    Timothy J Henrich
    Division of Infectious Disease, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Infect Dis 51:93-8. 2010
    ..However, there are no quantitative analyses supporting this hypothesis...
  38. ncbi request reprint High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004
    Roger Paredes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts, USA
    AIDS 21:2103-6. 2007
    ....
  39. pmc In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject
    Athe M N Tsibris
    Massachusetts General Hospital, Boston, Massachusetts, USA
    J Virol 82:8210-4. 2008
    ..Pretreatment V3 loop sequences reemerged following VCV discontinuation, implying that VCV resistance has associated fitness costs...
  40. pmc Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211
    Zhaohui Su
    Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 200:1724-8. 2009
    ..91 versus -0.57 log(10) copies/mL at week 24, respectively. Results suggest that the enhanced-sensitivity assay is a better screening tool for determining patient eligibility for CCR5 antagonist therapy...
  41. ncbi request reprint Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase
    Zixin Hu
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, and Division of AIDS, Harvard Medical School, Boston, MA, USA
    J Acquir Immune Defic Syndr 45:494-500. 2007
    ..These results show that Delta70 enhances resistance to certain purine and pyrimidine analogues and contributes to multinucleoside resistance in the appropriate viral genetic background...
  42. pmc Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide
    Vincent Marconi
    Section of Retroviral Therapeutics, Brigham and Women s Hospital and Division of AIDS, Harvard Medical School, Boston, MA 02139, USA
    J Acquir Immune Defic Syndr 48:572-6. 2008
    ..Subsequently, ENF was readministered for 4 weeks as "pulse intensification."..
  43. ncbi request reprint Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease
    Christina M R Kitchen
    Department of Biostatistics, University of California, Los Angeles, Los Angeles, California 90095, Section of Retroviral Therapeutics, Brigham and Women s Hospital, Boston, MA 02115, USA
    AIDS Res Hum Retroviruses 22:1260-6. 2006
    ..In contrast to observations when all drugs are interrupted, loss of resistance during enfuvirtide interruption is most likely due to ongoing viral evolution (and back-mutation), rather than emergence of an archived virus...
  44. pmc Tropism testing in the clinical management of HIV-1 infection
    Nina H Lin
    Infectious Diseases Unit, Massachusetts General Hospital, Boston, Massachusetts, USA
    Curr Opin HIV AIDS 4:481-7. 2009
    ..A variety of methods are available to determine HIV-1 co-receptor usage, commonly referred to as viral tropism. This article reviews recent data on phenotypic and genotypic assays of HIV-1 tropism...
  45. doi request reprint The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essential
    Rochelle P Walensky
    Divisions of 1Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Infect Dis 50:272-5. 2010
    ..We further address the substantial impact PEPfAR has achieved in general and more specifically toward improving maternal and child health and why continued PEPfAR investment remains essential...
  46. doi request reprint Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
    Martin S Hirsch
    Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 47:266-85. 2008
    ..As the roll out of antiretroviral therapy continues in developing countries, drug resistance monitoring for both subtype B and non-subtype B strains of HIV will become increasingly important...
  47. ncbi request reprint Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel
    Martin S Hirsch
    Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 37:113-28. 2003
    ..Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation...
  48. ncbi request reprint Current management challenges in HIV: antiretroviral resistance
    Daniel R Kuritzkes
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    AIDS Read 13:133-5, 138-42. 2003
    ..However, there is a need for additional trials to better define the role resistance testing may play in developing management approaches to mitigate or minimize emergence of resistant HIV...
  49. pmc In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine
    Roger Paredes
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Virol 83:2038-43. 2009
    ..After a lag phase of variable duration, wild-type variants emerged due to continued evolution of pol and back mutation rather than through emergence of an archived wild-type variant...
  50. doi request reprint Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary
    Richard A Murphy
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Infect Dis 196:S449-56. 2007
    ....
  51. pmc Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20)
    Jing Lu
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, and Division of AIDS, Harvard Medical School, Boston, Massachusetts 02139, USA
    J Virol 78:4628-37. 2004
    ..Further studies are needed to determine whether the reduced fitness of ENF-resistant viruses alters their pathogenicity in vivo...
  52. pmc The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates
    Nina H Lin
    Infectious Diseases Unit, Massachusetts General Hospital, 55 Fruit Street, Jackson 504, Boston, MA 02114, USA
    J Virol Methods 169:39-46. 2010
    ..This assay provides a sensitive, efficient and relatively low-cost approach suitable for use by research laboratories for assessing HIV-1 coreceptor usage of plasma samples...
  53. ncbi request reprint Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study
    Heather J Ribaudo
    Statistical Data Analysis Center, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 42:401-7. 2006
    ..Lower plasma efavirenz clearance is associated with a cytochrome P450 2B6 gene (CYP2B6) polymorphism (516G-->T) that is more frequent among African American individuals than among European American individuals...
  54. pmc Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis
    Jonathan Z Li
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Harvard Medical School, Harvard University, Boston, Massachusetts 02139, USA
    JAMA 305:1327-35. 2011
    ....
  55. ncbi request reprint Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations
    Roger Paredes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital and Division of AIDS, Harvard Medical School, Boston, MA, USA
    J Virol Methods 146:136-46. 2007
    ..In addition, ASPCR can be used to assess the dynamics of mutant populations in the viral quasispecies in response to changing selection pressures, allowing inferences on viral fitness in vivo through mathematical modeling...
  56. ncbi request reprint Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis
    Jing Lu
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, and Division of AIDS, Harvard Medical School, Boston, MA, USA
    J Acquir Immune Defic Syndr 43:60-4. 2006
    ..To study the dynamics of enfuvirtide (T-20) resistance development in HIV-1-infected subjects...
  57. pmc The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
    Florencia Pereyra
    Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology MIT and Harvard, Boston, MA, USA
    Science 330:1551-7. 2010
    ..These results implicate the nature of the HLA-viral peptide interaction as the major factor modulating durable control of HIV infection...
  58. ncbi request reprint Drug development strategies for salvage therapy: conflicts and solutions
    Victor De Gruttola
    Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    AIDS Res Hum Retroviruses 22:1106-9. 2006
  59. ncbi request reprint Drug resistance. Navigating resistance pathways
    Daniel Kuritzkes
    Harvard Medical School, Boston, Massachusetts, USA
    AIDS Read 12:395-400, 407. 2002
    ..The growing complexity of the HIV-1 resistance spectrum calls for more sophisticated testing and clinical expertise, in addition to more effective drugs...
  60. pmc Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211
    Athe M N Tsibris
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 48:642-9. 2009
    ....
  61. pmc Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions
    Noriaki Hosoya
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Microbiol 47:2604-6. 2009
    ..Concordance with the Trofile assay was good, but assays using replicating viruses did not increase substantially the ability to detect the presence of CXCR4-using virus...
  62. ncbi request reprint Clonal CD8+ T cell expansions in peripheral blood from human immunodeficiency virus type 1-infected children
    Elizabeth J McFarland
    Division of Pediatric Infectious Diseases, University of Colorado Health Sciences Center, Denver 80262, USA
    J Infect Dis 186:477-85. 2002
    ..Children with expansions were not more likely to have increased numbers of CD8(+) T cells, a finding consistent with the possibility that the CD8(+) TCR repertoire has limited diversity...
  63. pmc Monitoring HIV treatment in developing countries
    Serena P Koenig
    Division of Social Medicine and Health Inequalities, Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
    BMJ 332:602-4. 2006
  64. pmc Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness
    Zixin Hu
    Section of Retroviral Therapeutics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    J Acquir Immune Defic Syndr 55:148-55. 2010
    ..These findings correspond well with the clinical trials data and help explain the temporal pattern of RAL resistance evolution...
  65. ncbi request reprint Management of patients with virologic and metabolic failure
    Daniel R Kuritzkes
    Harvard Medical School, Brigham and Women s Hospital, Boston, USA
    AIDS Read 13:S17-22. 2003
    ..No one approach can be recommended for all patients, because the pattern of drug resistance and other factors such as regimen complexity, toxicities, and disease stage must be taken into account...
  66. ncbi request reprint HIV resistance: frequency, testing, mechanisms
    Daniel R Kuritzkes
    Harvard Medical School, Boston, MA, USA
    Top HIV Med 15:150-4. 2007
    ..This article summarizes a presentation on HIV resistance made by Daniel R. Kuritzkes, MD, at an International AIDS Society-USA Continuing Medical Education course in San Francisco in May 2007...
  67. ncbi request reprint Chemokine antagonists as therapeutics: focus on HIV-1
    Athe M N Tsibris
    Infectious Disease Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Annu Rev Med 58:445-59. 2007
    ..Pilot studies of orally bioavailable small-molecule CCR5 inhibitors in HIV-1-infected subjects have provided proof of concept for this novel drug class; phase III safety and efficacy trials are under way...
  68. pmc Emerging nanotechnology approaches for HIV/AIDS treatment and prevention
    Tewodros Mamo
    Laboratory of Nanomedicine and Biomaterials, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Nanomedicine (Lond) 5:269-85. 2010
    ....
  69. ncbi request reprint Adipocyte-derived hormone levels in HIV lipodystrophy
    Lisa Kosmiski
    Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Health Sciences Center, Denver, Col, USA
    Antivir Ther 8:9-15. 2003
    ..We examined the relationships of plasma leptin and adiponectin levels to fat distribution and insulin sensitivity in the HIV lipodystrophy syndrome...
  70. pmc Integrating microfluidics and lensless imaging for point-of-care testing
    Sangjun Moon
    Bio Acoustic MEMS in Medicine BAMM Laboratory, Center for Biomedical Engineering, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Biosens Bioelectron 24:3208-14. 2009
    ..The integrated platform points a promising direction for point-of-care testing (POCT) to rapidly capture, image and count subpopulations of cells from blood samples in an automated matter...
  71. pmc Quantum dot-based HIV capture and imaging in a microfluidic channel
    Yun Gon Kim
    Bio Acoustic MEMS in Medicine Laboratory, Center for Biomedical Engineering, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Cambridge, MA 02139, United States
    Biosens Bioelectron 25:253-8. 2009
    ..This on-chip HIV capture and imaging platform creates new avenues for point-of-care diagnostics and monitoring applications of infectious diseases...
  72. ncbi request reprint A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128
    David W Haas
    Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    HIV Clin Trials 4:287-300. 2003
    ..Human DNA banks must allow future analyses while addressing confidentiality, ethical, and regulatory issues...
  73. pmc Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1
    Zixin Hu
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts, USA
    J Virol 85:11309-14. 2011
    ..These results suggest that the E138K and M184I/V mutations are mutually compensatory and may explain the frequent occurrence of E138K/M184I after the virologic failure of rilpivirine-, lamivudine-, and emtricitabine-containing regimens...
  74. ncbi request reprint When more is less
    Daniel R Kuritzkes
    Clin Infect Dis 39:559-60. 2004
  75. ncbi request reprint Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
    Jacob P Lalezari
    Quest Clinical Research, Mount Zion Hospital and the University of California, San Francisco, San Francisco 94115, USA
    N Engl J Med 348:2175-85. 2003
    ..The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor...
  76. ncbi request reprint Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease
    Hernan Valdez
    Case Western Reserve University, University Hospitals of Cleveland Center for AIDS Research, Ohio, USA
    AIDS 16:1859-66. 2002
    ..To describe the magnitude of immune restoration after long-term control of HIV-1 replication. DESIGN Prospective study of immune restoration in patients starting highly active antiretroviral therapy (HAART)...
  77. ncbi request reprint Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370
    Jeonnette R Ickovics
    Department of Epidemiology and Public Health, Yale University School of Medicine, and Yale Center for Interdisciplinary Research on AIDS, New Haven, Conn, USA
    Antivir Ther 7:185-93. 2002
    ....
  78. ncbi request reprint Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients
    Gail Skowron
    Roger Williams Medical Center, Providence, Rhode Island 02908, USA
    J Infect Dis 186:1028-33. 2002
    ....
  79. pmc Accuracy of the TRUGENE HIV-1 genotyping kit
    Robert M Grant
    Gladstone Institute of Virology and Immunology, San Francisco, CA 94141, USA
    J Clin Microbiol 41:1586-93. 2003
    ..This integrated assay system for the detection of HIV-1 drug resistance mutations has a high degree of accuracy and reproducibility in several laboratories...
  80. ncbi request reprint Role of Baseline pol Genotype in HIV-1 Fitness Evolution
    Jan Weber
    Department of Virology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Acquir Immune Defic Syndr 33:448-60. 2003
    ..65, P < 0.0001). However, our results suggest that the preexistence of secondary mutations in protease genetic background may have implications in HIV-1 fitness evolution and virologic response to antiretroviral therapy...
  81. ncbi request reprint Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel
    Martin S Hirsch
    Top HIV Med 11:150-4. 2003
    ..We are happy to feature the latest edition in this issue of Topics in HIV Medicine. It is our hope that addressing these issues will help guide your treatment strategy decisions regarding resistance testing...
  82. ncbi request reprint Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen
    Steven G Deeks
    University of California, San Francisco, San Francisco, CA 94110, USA
    J Infect Dis 195:387-91. 2007
    ..Although enfuvirtide resistance mutations are associated with significant fitness defects in vivo, the clinical significance of these mutations remains undefined...
  83. ncbi request reprint Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation
    Joseph J Eron
    AIDS Clinical Research Unit, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Acquir Immune Defic Syndr 37:1581-3. 2004
    ..Nucleoside analogue reverse transcriptase inhibitors may have continued ARV activity despite long durations of partially suppressive therapy and the presence of resistant HIV-1...
  84. ncbi request reprint Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)
    Barbara M Gripshover
    University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA
    Antivir Ther 11:619-23. 2006
    ..Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type and NRTI-resistant viruses...
  85. ncbi request reprint Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection
    Mark A Wainberg
    McGill University AIDS Center, Lady Davis Institute Jewish General Hospital, Montreal, QC, Canada
    Antivir Ther 10:13-28. 2005
    ..The successful development of new NRTIs will depend upon a thorough appreciation of these many and complex issues, not only among those involved in the design of clinical studies, but also those contributing to their review and conduct...
  86. ncbi request reprint Update of the drug resistance mutations in HIV-1: Fall 2006
    Victoria A Johnson
    Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
    Top HIV Med 14:125-30. 2006
    ..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility...
  87. ncbi request reprint Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial
    Roy M Gulick
    Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY, USA
    JAMA 296:769-81. 2006
    ..Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen...
  88. ncbi request reprint Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study)
    Andrew R Zolopa
    Stanford University School of Medicine, Stanford, CA 94305 5107, USA
    Clin Infect Dis 41:92-9. 2005
    ..We sought to determine how much agreement exists within a group of experts in the interpretation of complex genotypes...
  89. ncbi request reprint Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence
    Hulin Wu
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, NY 14642, USA
    J Pharmacokinet Pharmacodyn 33:399-419. 2006
    ..But their combinations in viral dynamic modeling significantly predicted virologic response. The HIV dynamic modeling can appropriately capture complicated nonlinear relationships and interactions among multiple covariates...
  90. ncbi request reprint Update of the drug resistance mutations in HIV-1: Fall 2005
    Victoria A Johnson
    Veterans Affairs Medical Center, Birmingham, AL, USA
    Top HIV Med 13:125-31. 2005
    ..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility...
  91. ncbi request reprint Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials
    Mark Nelson
    Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 40:404-12. 2005
    ....
  92. ncbi request reprint Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen
    Daniel R Kuritzkes
    J Infect Dis 192:1867-8. 2005
  93. ncbi request reprint HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211
    Timothy J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Cornell Medical College, New York, NY, USA
    Clin Infect Dis 44:591-5. 2007
    ..Chemokine coreceptor use impacts both the natural history of human immunodeficiency virus type 1 (HIV-1) disease and the potential use of a new class of antiretroviral agents, the CCR5 inhibitors...
  94. ncbi request reprint Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)
    Cecilia M Shikuma
    Hawaii AIDS Clinical Research Program, John A Burns School of Medicine, University of Hawaii at Manoa, Manoa Leihi Hospital, 3675 Kilauea Avenue, Honolulu, HI 96816, USA
    J Acquir Immune Defic Syndr 44:540-50. 2007
    ..To assess metabolic changes after initiation of protease inhibitor (PI)-sparing regimens in antiretroviral-naive patients...
  95. ncbi request reprint Drug resistance mutations in HIV-1
    Victoria A Johnson
    Veterans Affairs Medical Center, and University of Alabama School of Medicine, Birmingham, AL, USA
    Top HIV Med 11:215-21. 2003
    ..Drugs that have been approved by the US Food and Drug Administration (FDA) or available through expanded access protocols are included...
  96. pmc In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA
    Mark Sharkey
    Program in Molecular Medicine, University of Massachusetts, 373 Plantation St, Biotech 2, Suite 319, Worcester, MA 01605, USA
    J Virol 79:5203-10. 2005
    ..Therefore, evolution of episomal viral cDNAs is a valid surrogate of ongoing viral replication in HIV-1-infected individuals...
  97. ncbi request reprint Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy
    Jeff D Moore
    University of Alabama at Birmingham, Division of Clinical Pharmacology, Birmingham, AL, USA
    Antivir Ther 12:981-6. 2007
    ..Little is known about how commonly used dual-NRTI regimens affect the intracellular levels of NRTI-TPs, the active form of these drugs. This study investigates the effect of dual-NRTI therapy in intracellular NRTI-TP levels...
  98. ncbi request reprint Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
    Roy M Gulick
    Weill Medical College of Cornell University, New York, USA
    N Engl J Med 350:1850-61. 2004
    ....
  99. ncbi request reprint A comparison of three initial antiretroviral AIDS regimens
    Heather J Ribaudo
    N Engl J Med 357:1056-7. 2007
  100. ncbi request reprint TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals
    Jacques Reynes
    Hopital Gui de Chauliac, CHU Montpellier, France
    AIDS Patient Care STDS 21:533-43. 2007
    ..In conclusion, these data demonstrate durable efficacy and safety of ENF over 96 weeks and that early use of ENF in combination with other agents for the treatment of antiretroviral-experienced HIV-infected subjects is beneficial...
  101. ncbi request reprint A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Antivir Ther 12:531-41. 2007
    ..Clinical stability has been observed with continued antiretroviral therapy (ART) in the setting of partial virological suppression. The optimal time to switch treatment in patients with low but detectable HIV-1 RNA is not known...

Research Grants25

  1. HIV-1 resistance to nucleoside analogues
    Daniel Kuritzkes; Fiscal Year: 2004
    ..Better understanding of the virologic, genetic, and biochemical aspects of AZT/3TC dual resistance will help direct therapy and may lead to better therapeutic strategies in the future. ..
  2. HIV-1 Resistance to Chemokine Receptor Antagonists
    Daniel Kuritzkes; Fiscal Year: 2007
    ....
  3. HIV-1 THERAPEUTICS AND DRUG RESISTANCE
    Daniel Kuritzkes; Fiscal Year: 2005
    ..This research program provides a framework within which the applicant can mentor beginning clinical investigators in patient-oriented research focused on these critical issues in HIV-1 medicine. ..
  4. HIV-1 DUAL RESISTANCE TO AZT AND 3TC
    Daniel Kuritzkes; Fiscal Year: 2000
    ..coli expression vectors and purified to near homogeneity. Mechanistic studies with reconstituted p66/p51 heterodimers will be performed using synthetic homopolymeric, as well as native heteromeric, RNA templates. ..
  5. HIV-1 THERAPEUTICS AND DRUG RESISTANCE
    Daniel Kuritzkes; Fiscal Year: 2009
    ..This research program provides a framework within which the applicant can mentor beginning clinical investigators in patient-oriented research focused on critical issues in HIV-1 medicine. ..
  6. Fitness of Enfuvirtide-(T-20)-Resistant HIV-1
    Daniel Kuritzkes; Fiscal Year: 2006
    ..Results of these studies will provide a deeper understanding of the molecular, virologic, and clinical consequences ofT-20 resistance, and may help guide the use of T-20 in salvage therapy. ..
  7. Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTU
    Daniel Kuritzkes; Fiscal Year: 2007
    ..administrative component ..
  8. HIV-1 THERAPEUTICS AND DRUG RESISTANCE
    Daniel Kuritzkes; Fiscal Year: 2007
    ..This research program provides a framework within which the applicant can mentor beginning clinical investigators in patient-oriented research focused on critical issues in HIV-1 medicine. ..
  9. Fitness of Enfuvirtide-(T-20)-Resistant HIV-1
    Daniel Kuritzkes; Fiscal Year: 2003
    ..Results of these studies will provide a deeper understanding of the molecular, virologic, and clinical consequences ofT-20 resistance, and may help guide the use of T-20 in salvage therapy. ..
  10. HIV-1 THERAPEUTICS AND DRUG RESISTANCE
    Daniel R Kuritzkes; Fiscal Year: 2010
    ..This research program provides a framework within which the applicant can mentor beginning clinical investigators in patient-oriented research focused on critical issues in HIV-1 medicine. ..